Skip to content
lifestyle.dietfitnessforall.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Outlook Therapeutics, Inc.
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
August 6, 2026
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
July 24, 2026
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
May 15, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
April 23, 2026
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 22, 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
April 21, 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 7, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026
1
2
Next Page
→